# A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

> **NCT07264634** · — · RECRUITING · sponsor: **Ascendis Pharma A/S** · enrollment: 10 (estimated)

## Conditions studied

- Hypoparathyroidism

## Interventions

- **DRUG:** Palopegteriparatide

## Key facts

- **NCT ID:** NCT07264634
- **Lead sponsor:** Ascendis Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-19
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07264634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07264634, "A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07264634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*